RSV is a leading cause of pneumonia in the elderly.
European regulators have approved the region's first vaccine for respiratory syncytial virus (RSV), which causes thousands of hospitalisations and deaths annually.
The shot, called Arexvy, is made by British drugmaker GSK and is designed to protect people aged 60 and over.
RSV typically causes cold-like symptoms, but is a leading cause of pneumonia in toddlers and the elderly.
The complex molecular structure of the virus and safety concerns with previous vaccine attempts had stymied efforts to successfully develop a shot since the virus was first discovered in 1956.
The approval this morning by the European Commission, which follows a recent endorsement from the European Medicines Agency, comes about a month after the US health regulator the gave Arexvy the green light.
The availability of the vaccine in Europe will depend on national recommendations and reimbursement discussions, but the first launches are expected this autumn ahead of the 2023/2024 RSV season, GSK said in a statement.
The company said it does not expect a significant rollout in Europe this year
Naas Clinic Among Highest Earners From Medical Cert Scheme
Kildare-Based Animal Rescue Group Continue Calls To Ban Sulky Racing On Public Roads
National Homeless Figures Increased By Almost 200 In February
Trial Date Set For Man Accused Of Attempted Murder Of Three Children In Dublin attack
Piper’s Hill College Among Schools Awarded National LGBTQ+ Quality Mark
North Kildare Road Closures Planned As Major Water Works Get Underway
Planning Approved for €260m Expansion of Newbridge Brewery
€100,000 Spent Repairing Historic Kildare Canal Bridge After Repeated Crashes
